Biohaven Ltd. (NYSE: BHVN) (Biohaven) on Saturday presented preclinical data for BHV-1420 in an oral presentation at the ...

Biohaven Ltd. (NYSE: BHVN) (Biohaven) on Saturday presented preclinical data for BHV-1420 in an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado.

Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study ...

Climb Bio reported immunologic remission in five of 13 pMN patients at 12 weeks. Its uncontrolled Phase 2 trial has more data ...

In a laboratory diagnostic assay, BHV-1420 brought 88% of anti-PLA2R-positive patient samples (n=59) below the clinical threshold for positivity, indicating its potential to recognize and target ...

I will start with the conclusion. As of today, there are 104 days left until the Nephrology Specialist Exam (written exam on January 30, 2027), which is almost exactly 3 months. Instead of publishing ...

Idiopathic membranous nephropathy (IMN) is frequently driven by autoantibodies targeting phospholipase A2 receptor 1 (PLA2R), resulting in immune-mediated glomerular injury and proteinuria.

Biohaven Ltd. a présenté samedi des données précliniques sur BHV-1420 lors d’une présentation orale à l’occasion de la Kidney ...

Climb Bio, Inc. a annoncé de nouvelles données cliniques concernant le budoprutug, son anticorps monoclonal anti-CD19, dans ...

Biohaven Ltd. presentó el sábado datos preclínicos sobre el BHV-1420 durante una ponencia oral en la Kidney Week 2026 de la ...

Biohaven Ltd. presenteerde zaterdag tijdens een mondelinge presentatie op Kidney Week 2026 van de American Society of Nephrology in Denver, Colorado, preklinische gegevens over BHV-1420.